Back to results
US 2026/0185992 A1Published application
Methods for selecting and treating patients with retinal disease based on complement pathway hyperactivity
AssigneeOak Bay Biosciences Inc.
InventorCarl Erickson
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating a subject with a complement pathway inhibitor based on the subject's complement pathway activity. Also provided herein are methods of stratifying a subject into three groups based on the subject's complement pathway activity: hyperactive, homeostatic, and hypoactive, and administering an effective treatment (e.g., complement pathway inhibitors).
Claims28
A method of treating a subject in need thereof, the method comprising:
- identifying or having identified the subject as having hyperactive complement pathway activity or not having hyperactive complement pathway activity;
- and
- (a) when the subject is identified as having hyperactive complement pathway activity, administering to the subject, or recommending that the subject be treated with, a complement pathway inhibitor;
- or
- (b) when the subject is identified as not having hyperactive complement pathway activity, administering to the subject, or recommending that the subject be treated with, a therapy other than a complement pathway inhibitor,
- wherein the subject has hyperactive complement pathway activity when:
- (i) a concentration of Ba fragment of Factor B present in an ocular fluid of the subject is greater than or equal to about 18 ng/ml,
- (ii) a concentration of Bb fragment of Factor B present in an ocular fluid of the subject is greater than or equal to about 140 ng/ml,
- (iii) or both.
6 more elements
Dependencies are inferred from the claim text.